Home › Funds › SR ONE CAPITAL MANAGEMENT, LP › SPRY
SR ONE CAPITAL MANAGEMENT, LP position in SPRY
ARS PHARMACEUTICALS INC · Health Care
SR ONE CAPITAL MANAGEMENT, LP reported holding 4,012,903 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$32.1M, representing 3.09% of its reported portfolio and ranking #10 among its reported holdings. SR ONE CAPITAL MANAGEMENT, LP has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SR ONE CAPITAL MANAGEMENT, LP's SPRY position evolved
SR ONE CAPITAL MANAGEMENT, LP first disclosed a stake in SPRY in Q3 2023 at 4,012,903 shares (US$15.2M). The position peaked in Q2 2025 at 4,012,903 shares, worth US$70.0M. Across 12 filings, SR ONE CAPITAL MANAGEMENT, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 4,012,903 shares valued at US$32.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.01M | $15.17M | New |
| Q4 2023 | 4.01M | $21.99M | Hold |
| Q1 2024 | 4.01M | $41.01M | Hold |
| Q2 2024 | 4.01M | $34.15M | Hold |
| Q3 2024 | 4.01M | $58.19M | Hold |
| Q4 2024 | 4.01M | $42.34M | Hold |
| Q1 2025 | 4.01M | $50.48M | Hold |
| Q2 2025 | 4.01M | $70.03M | Hold |
| Q3 2025 | 4.01M | $40.33M | Hold |
| Q4 2025 | 4.01M | $46.75M | Hold |
| Q1 2026 | 4.01M | $32.22M | Hold |
| Q2 2026 | 4.01M | $32.14M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 24 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- RA CAPITAL MANAGEMENT, L.P. 10.86M sh · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M sh · $68.41M · Q2 2026
- ORBIMED ADVISORS LLC 8.29M sh · $66.39M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M sh · $60.11M · Q2 2026
- Tyro Capital Management LLC 4.46M sh · $35.72M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.13M sh · $9.08M · Q2 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
- Third Point LLC 1.00M sh · $8.01M · Q2 2026
- Tejara Capital Ltd 607.04K sh · $4.86M · Q2 2026
More on SR ONE CAPITAL MANAGEMENT, LP
FAQ
How long has SR ONE CAPITAL MANAGEMENT, LP held SPRY?
SR ONE CAPITAL MANAGEMENT, LP has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is SR ONE CAPITAL MANAGEMENT, LP's current position in SPRY?
As of Q2 2026, SR ONE CAPITAL MANAGEMENT, LP holds 4.01M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $32.14M, representing 3.09% of its reported portfolio and ranking #10.
Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling SPRY?
In the latest 13F filing (Q2 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in SPRY. The position peaked in Q2 2025 at 4.01M shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.